Your browser doesn't support javascript.
loading
Does day 11 omission of methotrexate due to toxicity influence the outcome in myeloablative hematopoietic cell transplant? Results from a single-center retrospective cohort study.
Hamilton, B K; Rybicki, L; Haddad, H; Abounader, D; Yurch, M; Majhail, N S; Hanna, R; Sobecks, R; Dean, R; Liu, H; Hill, B; Copelan, E; Bolwell, B; Kalaycio, M.
Afiliación
  • Hamilton BK; Bone Marrow Transplant Program, Department of Hematology & Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
  • Rybicki L; Quantitative Health Sciences, Cleveland Clinic Lerner Research Institute, Cleveland, OH, USA.
  • Haddad H; Department of Hematology/Oncology, Staten Island University Hospital, New York, NY, USA.
  • Abounader D; Bone Marrow Transplant Program, Department of Hematology & Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
  • Yurch M; Bone Marrow Transplant Program, Department of Hematology & Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
  • Majhail NS; Bone Marrow Transplant Program, Department of Hematology & Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
  • Hanna R; Department of Pediatric Hematology & Oncology, Cleveland Clinic, Cleveland, OH, USA.
  • Sobecks R; Bone Marrow Transplant Program, Department of Hematology & Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
  • Dean R; Bone Marrow Transplant Program, Department of Hematology & Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
  • Liu H; Bone Marrow Transplant Program, Department of Hematology & Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
  • Hill B; Bone Marrow Transplant Program, Department of Hematology & Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
  • Copelan E; Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA.
  • Bolwell B; Bone Marrow Transplant Program, Department of Hematology & Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
  • Kalaycio M; Bone Marrow Transplant Program, Department of Hematology & Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
Blood Cancer J ; 5: e344, 2015 Aug 28.
Article en En | MEDLINE | ID: mdl-26314986
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Metotrexato / Trasplante de Células Madre Hematopoyéticas / Enfermedad Injerto contra Huésped / Inmunosupresores Tipo de estudio: Etiology_studies / Observational_studies Idioma: En Revista: Blood Cancer J Año: 2015 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Metotrexato / Trasplante de Células Madre Hematopoyéticas / Enfermedad Injerto contra Huésped / Inmunosupresores Tipo de estudio: Etiology_studies / Observational_studies Idioma: En Revista: Blood Cancer J Año: 2015 Tipo del documento: Article